-
Palivizumab
- indication:For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
- pharmacologypharmacology:
- mechanism: Palivizumab binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.
- toxicity:
- absorprion:
- halflife: 18-20 days (in adults)
- roouteelimination:
- volumedistribution:
- clearance: